Online inquiry

IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14064MR)

This product GTTS-WQ14064MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14064MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11151MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ12561MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ10174MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ12197MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ8459MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ15962MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ478MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ9584MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW